Technical Analysis for SVA - Sinovac Biotech, Ltd. (Antigua/Barbudo)

Grade Last Price % Change Price Change
grade F 6.47 -0.31% -0.02
SVA closed down 0.31 percent on Friday, February 22, 2019, on 61 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical SVA trend table...

Date Alert Name Type % Chg
Feb 22 20 DMA Resistance Bearish 0.00%
Feb 22 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Feb 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 22 Bollinger Band Squeeze Range Contraction 0.00%
Feb 22 Doji - Bullish? Reversal 0.00%
Feb 22 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Feb 22 Outside Day Range Expansion 0.00%
Feb 22 Lower Bollinger Band Touch Weakness 0.00%
Feb 21 20 DMA Resistance Bearish -0.31%
Feb 21 1,2,3 Retracement Bearish Bearish Swing Setup -0.31%

Older signals for SVA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Its products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and RabEnd, a animal rabies vaccine. The company has also completed a phase I clinical trial of a SARS vaccine. In addition, it develops the EV71 vaccine, which has completed clinical trials. Further, the company develops a pipeline of vaccine candidates in the clinical and pre-clinical development phases, including human vaccines for pneumococcal, rotavirus, rabies, varicella, and rubella that are in pre-clinical stage. It has a collaboration agreement with Tianjing CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.
Medicine Biotechnology Biopharmaceutical Vaccination Vaccines Hepatitis B Influenza Vaccine Rabies Virology Hepatitis A Influenza Viruses Mumps Rubella Varicella
Is SVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.75
52 Week Low 5.73
Average Volume 13,382
200-Day Moving Average 7.2378
50-Day Moving Average 6.6398
20-Day Moving Average 6.4995
10-Day Moving Average 6.497
Average True Range 0.1907
ADX 37.13
+DI 8.0733
-DI 27.6739
Chandelier Exit (Long, 3 ATRs ) 6.1179
Chandelier Exit (Short, 3 ATRs ) 6.8221
Upper Bollinger Band 6.6574
Lower Bollinger Band 6.3416
Percent B (%b) 0.41
BandWidth 4.858835
MACD Line -0.0507
MACD Signal Line -0.0593
MACD Histogram 0.0085
Fundamentals Value
Market Cap 368.59 Million
Num Shares 57 Million
EPS -0.08
Price-to-Earnings (P/E) Ratio -80.88
Price-to-Sales 6.26
Price-to-Book 3.48
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.97
Resistance 3 (R3) 6.95 6.76 6.88
Resistance 2 (R2) 6.76 6.64 6.77 6.85
Resistance 1 (R1) 6.62 6.56 6.53 6.64 6.83
Pivot Point 6.43 6.43 6.39 6.44 6.43
Support 1 (S1) 6.29 6.31 6.20 6.31 6.11
Support 2 (S2) 6.10 6.23 6.11 6.09
Support 3 (S3) 5.96 6.10 6.06
Support 4 (S4) 5.98